Ohr Pharmaceutical Inc (OHRP) 2.72 $OHRP
Heavily Oversold a Correction may be Forthcoming; Ohr Pharmaceuticals Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Ohr Pharmaceuticals, Inc. (NASDAQ: OHRP) is a New York based pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs, recently announced disappointing topline results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% Squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). OHRP shares plunged 68.6% immediately after the company reported disappointing top-line results from an exploratory phase II study. Shares have yet to recover, but a potential upside exists.
OHRP: 2.72 (+0.08)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), NVAX: 8.51 (+0.09), OHRP: 2.72 (+0.08), JUNO: 55.72 (-0.68), MNKD: 4.90 (-0.09)
4 Stocks Under $10 Making Big Moves
at The Street - Tue Apr 07, 1:16PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BIOS: 5.23 (+0.04), OHRP: 2.72 (+0.08), CLF: 5.08 (+0.03), BLRX: 2.12 (unch)
Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
The Pump Stopper - at Seeking Alpha - Tue Apr 07, 11:23AM CDT
I believe Cellular Biomedicine (NASDAQ: CBMG ) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside. CBMG was previously focusing on Nintendo screens...
NBS: 2.88 (+0.06), IBB: 363.84 (-0.66), OHRP: 2.72 (+0.08), CBMG: 32.14 (+2.21)
OHR Pharmaceutical (OHRP) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:41AM CDT
OHR Pharmaceutical (OHRP) Enters Oversold Territory
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 2:50PM CDT
Ohr Pharmaceutical (OHRP) reported disappointing top-line results from a phase II study evaluating OHR-102 combination therapy for the treatment of patients suffering from the wet form of age-related macular degeneration.
SLXP: 172.96 (+0.15), OHRP: 2.72 (+0.08), REGN: 472.63 (+9.41)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.12), CRMD: 8.86 (-0.28), NCFT: 25.87 (+0.17), LEJU: 9.16 (+0.65), CTRX: 59.46 (-0.11), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), CNAT: 6.31 (-0.15), XON: 44.53 (+0.36), BBEP: 6.40 (-0.10), ADMP: 4.66 (-0.01), CLDN: 13.59 (-2.77), ASPX: 100.79 (+0.09), HPTX: 45.96 (-0.18), GENE: 4.88 (-0.05), SYN: 2.31 (-0.07), ICEL: 16.47 (-0.02), HZNP: 30.96 (+0.10), OHRP: 2.72 (+0.08), SFUN: 7.82 (+0.64), CNET: 1.56 (unch)
Dow Chemical and Carnival are big market movers
AP - Fri Mar 27, 4:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
BB.TO: 12.13 (-0.20), CCL: 46.62 (+0.03), OLN: 31.10 (-0.04), ALTR: 42.78 (-0.46), BBRY: 9.92 (-0.11), OXM: 79.42 (-0.53), DOV: 71.89 (-0.04), OHRP: 2.72 (+0.08), INTC: 32.70 (+0.27), ROLL: 75.54 (+0.32), DOW: 50.02 (+0.37)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OHR PHARMACEUTICAL, INC. -- OHRP
PR Newswire - Fri Mar 27, 3:45PM CDT
Levi & Korsinsky announces it has commenced an investigation of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) concerning possible violations of federal securities laws. The investigation concerns certain statements issued by the Company in connection with its study of the drug OHR-102. To obtain additional information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
OHRP: 2.72 (+0.08)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 69.31 (-0.40), BIIB: 423.57 (+1.46), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HUM: 180.01 (-0.12), MEIP: 2.08 (-0.16), DVA: 83.22 (+0.10), PFS: 18.65 (+0.06), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), HHS: 7.73 (-0.06), OHRP: 2.72 (+0.08), THRX: 17.08 (+0.45), REGN: 472.63 (+9.41)
Five Lessons From Ohr Pharma
Richard Pearson - at Seeking Alpha - Fri Mar 27, 12:21PM CDT
Five lessons from Ohr Pharma - Today shares of Ohr Pharmaceutical (NASDAQ: OHRP ) fell by more than 65% intraday following the announcement that its OHR-102 (Squalamine) eye drug failed to meet its primary goal. For those who lost money on Ohr, I...
UNXL: 5.76 (+0.01), ONVO: 5.14 (+0.67), CYTR: 5.21 (-0.06), OHRP: 2.72 (+0.08), GALE: 1.39 (unch)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Ohr Pharmaceutical, Inc. - OHRP
Business Wire - Fri Mar 27, 11:50AM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) resulting from allegations that Ohr Pharmaceutical may have issued materially misleading business information to the investing public.
OHRP: 2.72 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:45AM CDT
DHRM: 2.92 (+0.08), GGB: 3.28 (+0.20), BMRN: 121.08 (-0.16), OLN: 31.10 (-0.04), HCHC: 11.15 (+0.03), APDN: 2.65 (-0.02), ZQK: 1.76 (+0.03), OXM: 79.42 (-0.53), ROLL: 75.54 (+0.32), GVP: 1.51 (unch), MOLG: 2.30 (+0.05), CCIH: 14.86 (+2.54), GBSN: 4.98 (+1.44), EVAR: 4.30 (-0.19), LIME: 2.85 (-0.12), CALA: 12.93 (-1.06), OHRP: 2.72 (+0.08), INPH: 1.39 (-0.10), CARV: 4.86 (-0.04), GNI: 8.10 (+0.67)
Ohr Pharmaceuticals (OHRP) Stock Tanks Today Following Disappointing Test Results
at The Street - Fri Mar 27, 10:29AM CDT
Ohr Pharmaceuticals (OHRP) shares have dropped over 60% after the company revealed disappointing phase II results for its macular degeneration treatment.
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical: Undervalued Biotech Set To Possibly Challenge Regeneron's Eylea Drug
Long Term Bio - at Seeking Alpha - Fri Mar 27, 9:26AM CDT
OHRP: 2.72 (+0.08), REGN: 472.63 (+9.41)
Ohr Pharma shares will be <$3 today but Roth maintains "Buy" with $30 PT
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:57AM CDT
OHRP: 2.72 (+0.08)
Ohr's eye drug fails mid-stage study, shares plunge 44 pct
AP - Fri Mar 27, 7:40AM CDT
NEW YORK (AP) — Ohr Pharmaceutical's treatment for an eye condition that can lead to blindness failed to meet a key goal in a mid-stage study, sending shares down 44 percent before the opening bell Friday.
OHRP: 2.72 (+0.08)
Ohr Pharma Phase 2 study of wet-AMD drug fails to hit primary endpoint; shares plummet 55% premarket
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:23AM CDT
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
GlobeNewswire - Fri Mar 27, 6:00AM CDT
Positive Visual Acuity Benefit in Classic Containing CNV Using OHR-102 Combination Therapy
OHRP: 2.72 (+0.08)
Heavily Oversold a Correction may be Forthcoming; Ohr Pharmaceuticals Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Ohr Pharmaceuticals, Inc. (NASDAQ: OHRP) is a New York based pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs, recently announced disappointing topline results from the exploratory Phase II IMPACT study evaluating OHR-102 (0.2% Squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). OHRP shares plunged 68.6% immediately after the company reported disappointing top-line results from an exploratory phase II study. Shares have yet to recover, but a potential upside exists.
OHRP: 2.72 (+0.08)
Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), NVAX: 8.51 (+0.09), OHRP: 2.72 (+0.08), JUNO: 55.72 (-0.68), MNKD: 4.90 (-0.09)
4 Stocks Under $10 Making Big Moves
at The Street - Tue Apr 07, 1:16PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BIOS: 5.23 (+0.04), OHRP: 2.72 (+0.08), CLF: 5.08 (+0.03), BLRX: 2.12 (unch)
Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
The Pump Stopper - at Seeking Alpha - Tue Apr 07, 11:23AM CDT
I believe Cellular Biomedicine (NASDAQ: CBMG ) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside. CBMG was previously focusing on Nintendo screens...
NBS: 2.88 (+0.06), IBB: 363.84 (-0.66), OHRP: 2.72 (+0.08), CBMG: 32.14 (+2.21)
OHR Pharmaceutical (OHRP) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:41AM CDT
OHR Pharmaceutical (OHRP) Enters Oversold Territory
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 2:50PM CDT
Ohr Pharmaceutical (OHRP) reported disappointing top-line results from a phase II study evaluating OHR-102 combination therapy for the treatment of patients suffering from the wet form of age-related macular degeneration.
SLXP: 172.96 (+0.15), OHRP: 2.72 (+0.08), REGN: 472.63 (+9.41)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT
BDSI: 9.26 (+0.12), CRMD: 8.86 (-0.28), NCFT: 25.87 (+0.17), LEJU: 9.16 (+0.65), CTRX: 59.46 (-0.11), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), CNAT: 6.31 (-0.15), XON: 44.53 (+0.36), BBEP: 6.40 (-0.10), ADMP: 4.66 (-0.01), CLDN: 13.59 (-2.77), ASPX: 100.79 (+0.09), HPTX: 45.96 (-0.18), GENE: 4.88 (-0.05), SYN: 2.31 (-0.07), ICEL: 16.47 (-0.02), HZNP: 30.96 (+0.10), OHRP: 2.72 (+0.08), SFUN: 7.82 (+0.64), CNET: 1.56 (unch)
Dow Chemical and Carnival are big market movers
AP - Fri Mar 27, 4:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
BB.TO: 12.13 (-0.20), CCL: 46.62 (+0.03), OLN: 31.10 (-0.04), ALTR: 42.78 (-0.46), BBRY: 9.92 (-0.11), OXM: 79.42 (-0.53), DOV: 71.89 (-0.04), OHRP: 2.72 (+0.08), INTC: 32.70 (+0.27), ROLL: 75.54 (+0.32), DOW: 50.02 (+0.37)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OHR PHARMACEUTICAL, INC. -- OHRP
PR Newswire - Fri Mar 27, 3:45PM CDT
Levi & Korsinsky announces it has commenced an investigation of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) concerning possible violations of federal securities laws. The investigation concerns certain statements issued by the Company in connection with its study of the drug OHR-102. To obtain additional information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
OHRP: 2.72 (+0.08)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 69.31 (-0.40), BIIB: 423.57 (+1.46), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HUM: 180.01 (-0.12), MEIP: 2.08 (-0.16), DVA: 83.22 (+0.10), PFS: 18.65 (+0.06), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), CLLS: 31.30 (-0.91), HHS: 7.73 (-0.06), OHRP: 2.72 (+0.08), THRX: 17.08 (+0.45), REGN: 472.63 (+9.41)
Five Lessons From Ohr Pharma
Richard Pearson - at Seeking Alpha - Fri Mar 27, 12:21PM CDT
Five lessons from Ohr Pharma - Today shares of Ohr Pharmaceutical (NASDAQ: OHRP ) fell by more than 65% intraday following the announcement that its OHR-102 (Squalamine) eye drug failed to meet its primary goal. For those who lost money on Ohr, I...
UNXL: 5.76 (+0.01), ONVO: 5.14 (+0.67), CYTR: 5.21 (-0.06), OHRP: 2.72 (+0.08), GALE: 1.39 (unch)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Ohr Pharmaceutical, Inc. - OHRP
Business Wire - Fri Mar 27, 11:50AM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) resulting from allegations that Ohr Pharmaceutical may have issued materially misleading business information to the investing public.
OHRP: 2.72 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:45AM CDT
DHRM: 2.92 (+0.08), GGB: 3.28 (+0.20), BMRN: 121.08 (-0.16), OLN: 31.10 (-0.04), HCHC: 11.15 (+0.03), APDN: 2.65 (-0.02), ZQK: 1.76 (+0.03), OXM: 79.42 (-0.53), ROLL: 75.54 (+0.32), GVP: 1.51 (unch), MOLG: 2.30 (+0.05), CCIH: 14.86 (+2.54), GBSN: 4.98 (+1.44), EVAR: 4.30 (-0.19), LIME: 2.85 (-0.12), CALA: 12.93 (-1.06), OHRP: 2.72 (+0.08), INPH: 1.39 (-0.10), CARV: 4.86 (-0.04), GNI: 8.10 (+0.67)
Ohr Pharmaceuticals (OHRP) Stock Tanks Today Following Disappointing Test Results
at The Street - Fri Mar 27, 10:29AM CDT
Ohr Pharmaceuticals (OHRP) shares have dropped over 60% after the company revealed disappointing phase II results for its macular degeneration treatment.
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical: Undervalued Biotech Set To Possibly Challenge Regeneron's Eylea Drug
Long Term Bio - at Seeking Alpha - Fri Mar 27, 9:26AM CDT
OHRP: 2.72 (+0.08), REGN: 472.63 (+9.41)
Ohr Pharma shares will be <$3 today but Roth maintains "Buy" with $30 PT
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:57AM CDT
OHRP: 2.72 (+0.08)
Ohr's eye drug fails mid-stage study, shares plunge 44 pct
AP - Fri Mar 27, 7:40AM CDT
NEW YORK (AP) — Ohr Pharmaceutical's treatment for an eye condition that can lead to blindness failed to meet a key goal in a mid-stage study, sending shares down 44 percent before the opening bell Friday.
OHRP: 2.72 (+0.08)
Ohr Pharma Phase 2 study of wet-AMD drug fails to hit primary endpoint; shares plummet 55% premarket
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 7:23AM CDT
OHRP: 2.72 (+0.08)
Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD
GlobeNewswire - Fri Mar 27, 6:00AM CDT
Positive Visual Acuity Benefit in Classic Containing CNV Using OHR-102 Combination Therapy
OHRP: 2.72 (+0.08)
